Synaptogenix Inc (SNPX)

[Antti]

Even though you weren't asking me to answer I would like to ask you one question.

Since it seems that we look at CU data so differently it would be interesting to know what's your approach and is there something to learn from it.

The way I see it CU patients are just like any patients who are participating on the trial. Yes, they know that they are getting the real drug (just like open label patients) and more resources are usually available for them. So there is possibility of stronger than average placebo effect for sure (just like in open label trials).

But what makes you think that the data we got from CU patients isn't that important or is somehow considerably inferior to the data the company gets from single patients participating on phase 2b trial?